A Key to Detecting Brain Disease Earlier Than Ever
![Wired](/sites/default/files/styles/large/public/2024-01/WW2024_-1469261051_HEALTH_Michael-J.-Fox-and-Deborah-W.-Brooks-.jpg?itok=Y-0DQFjn)
Earlier this year, Parkinson’s disease (PD) research entered a new era when the Michael J. Fox Foundation announced a momentous scientific breakthrough—the discovery of a biomarker for PD. It meant that, for the first time ever, we can now pinpoint the earliest known signs of the disease in Parkinson’s patients.
This long-awaited new procedure is called the “alpha-synuclein seeding amplification assay” (SAA), and it’s capable of detecting the misfolded alpha-synuclein in spinal fluid—the wayward protein clearly linked to Parkinson’s. It separates, with a stunning 90 percent specificity, those who have evidence of PD pathology in their cells from those who do not. It does so even before the emergence of symptoms, much like the way high blood pressure or cholesterol levels are used to detect cardiovascular risk long before a heart attack lands someone in the ER.
It would be hard to overstate the implications of this development for people living with dysfunction in their alpha-synuclein. For one thing, we’ve never had a way to know who these people are—that is, until the moment of diagnosis, by which point ongoing damage to brain cells is already well underway. As for the diagnosis itself, which for most people comes as a bolt from the blue, it has always been frustratingly subjective and essentially based on a physician’s opinion following a brief once-over in the doctor’s office—not very useful for medical care provision, let alone biomedical drug development.